Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
J Surg Res. 2021 Oct;266:27-34. doi: 10.1016/j.jss.2021.04.005. Epub 2021 May 8.
Signet-ring cell gastric cancer (SRGC) is a histological variant of gastric adenocarcinoma (GAC) with a worse prognosis compared to non-signet-ring cell gastric cancer (NSRGC). To our knowledge, the overall survival (OS) among patients with SRGC undergoing total/near-total (TG) versus partial gastrectomy (PG) has never been reported from a large-scale Western database.
We performed a retrospective analysis of patients with both SRGC and NSRGC using The National Cancer Database.
In total, 17,086 patients were included. Patients who underwent TG versus PG were 25.5% (n = 770) versus 74.5% (n = 2246) for SRGC, and 20.9% (n = 2943) versus 79.1% (n = 11,127) for NSRGC, respectively. Patients who had SRGC were more likely to undergo TG (25.5% versus 20.9% P< 0.0001). Patients with distal gastric tumors were less likely to undergo TG (16.5% versus 25.4% P < 0.0001). Patients undergoing PG for the SRGC histological variant had better OS (HR = 0.68, CI=0.61-0.76; P < 0.0001) versus those who underwent TG. Similarly, NSRGC patients undergoing PG also had improved OS, but to a lesser extent (HR = 0.91, CI = 0.85-0.96; P= 0.002). Overall, PG for GAC was associated with improved OS compared to TG, although the OS benefit is more profound in the SRGC histological variant (P < 0.0001).
Our results show that TG is not associated with improved OS in patients who undergo gastrectomy for GAC, even when adjusted for tumor location. The survival differences are more pronounced in the SRGC histology variant. The worst survival is observed in patients with SRGC who undergo TG after adjusting for different covariates.
印戒细胞胃癌(SRGC)是一种组织学上的胃腺癌(GAC)变体,与非印戒细胞胃癌(NSRGC)相比预后更差。据我们所知,来自大型西方数据库的报道从未报告过接受全胃/近全胃切除术(TG)与部分胃切除术(PG)的 SRGC 患者的总生存(OS)。
我们使用国家癌症数据库对 SRGC 和 NSRGC 患者进行了回顾性分析。
共纳入 17086 例患者。接受 TG 与 PG 的 SRGC 患者分别为 25.5%(n=770)和 74.5%(n=2246),NSRGC 患者分别为 20.9%(n=2943)和 79.1%(n=11127)。患有 SRGC 的患者更有可能接受 TG(25.5%比 20.9%,P<0.0001)。远端胃肿瘤患者更不可能接受 TG(16.5%比 25.4%,P<0.0001)。接受 PG 治疗的 SRGC 患者的 OS 更好(HR=0.68,CI=0.61-0.76;P<0.0001),而接受 TG 的患者则更差。同样,接受 PG 治疗的 NSRGC 患者的 OS 也有所改善,但程度较小(HR=0.91,CI=0.85-0.96;P=0.002)。总的来说,与 TG 相比,GAC 的 PG 与 OS 改善相关,尽管 SRGC 组织学变体的 OS 获益更显著(P<0.0001)。
我们的结果表明,即使在调整肿瘤位置后,TG 也与接受 GAC 胃切除术患者的 OS 改善无关。在 SRGC 组织学变体中,生存差异更为明显。在调整了不同协变量后,接受 TG 的 SRGC 患者的生存最差。